Potential clinically significant drug-drug interactions of hydroxychloroquine used in the treatment of COVID-19.

Published in: International journal of clinical practice (2021)

Using HCQ has clinical debate whether it should or should not continue in COVID-19 patients, however, potential clinically significant DDIs identified in this study may optimise safety or efficacy of HCQ in considerable proportion of patients.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
emergency department
patient reported outcomes